Policymakers are scrutinizing high prices for specialty drugs like never before. Gilead’s Sovaldi at $84,000 for a treatment course is in part to blame -- or credit -- for this, but so are Vertex’ Kalydeco, Merck’s Keytruda , and a series of other six figure drugs.
Policymakers are scrutinizing high prices for specialty drugs like never before. Gilead’s Sovaldi at $84,000 for a treatment course is in part to blame -- or credit -- for this, but so are Vertex’ Kalydeco, Merck’s Keytruda , and a series of other six figure drugs.
Share this Article
Comment on this Article
Recommended
Please to comment